TY - JOUR
T1 - Pentoxifylline in dermatology
AU - Balazic, Eliza
AU - Axler, Eden
AU - Konisky, Hailey
AU - Khanna, Urmi
AU - Kobets, Kseniya
N1 - Publisher Copyright:
© 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
PY - 2023/2
Y1 - 2023/2
N2 - Background: Pentoxifylline was initially marketed for use in patients with intermittent claudication due to chronic occlusive arterial disease of the extremities but has since been shown to have several off-label uses in dermatology. Aims: The aim of this review is to increase awareness of the several applications of pentoxifylline in the field of dermatology. Methods: A comprehensive PubMed search was conducted in May 2022 using the following phrases “dermatology” AND “pentoxifylline.” Our search period spanned 34 years from 1988 to 2022. All available literature was reviewed. Reference lists of identified articles were included. Studies were excluded if they were not in English and if the study was out of scope. Eighty-one articles were included in this review. Results: Pentoxifylline has been used to treat various dermatological conditions including peripheral vascular disease, vasculitis and vasculopathies, chilblains, pigmented purpuric dermatosis, granuloma annulare, necrobiosis, keloids, lichen sclerosis et atrophicus, scars, radiation-induced fibrosis, vitiligo, alopecia areata, leishmaniasis, and leprosy. Conclusions: Pentoxifylline's use in dermatology is growing. However, there are limited larger studies and randomized control trials on the use of pentoxifylline in dermatology and more investigation is needed to evaluate its use for many dermatologic conditions. Pentoxifylline's unique mechanism of action as well as its good tolerability, cost-effectiveness, and minimal drug interactions make it a convenient primary or adjunctive option in many dermatological conditions.
AB - Background: Pentoxifylline was initially marketed for use in patients with intermittent claudication due to chronic occlusive arterial disease of the extremities but has since been shown to have several off-label uses in dermatology. Aims: The aim of this review is to increase awareness of the several applications of pentoxifylline in the field of dermatology. Methods: A comprehensive PubMed search was conducted in May 2022 using the following phrases “dermatology” AND “pentoxifylline.” Our search period spanned 34 years from 1988 to 2022. All available literature was reviewed. Reference lists of identified articles were included. Studies were excluded if they were not in English and if the study was out of scope. Eighty-one articles were included in this review. Results: Pentoxifylline has been used to treat various dermatological conditions including peripheral vascular disease, vasculitis and vasculopathies, chilblains, pigmented purpuric dermatosis, granuloma annulare, necrobiosis, keloids, lichen sclerosis et atrophicus, scars, radiation-induced fibrosis, vitiligo, alopecia areata, leishmaniasis, and leprosy. Conclusions: Pentoxifylline's use in dermatology is growing. However, there are limited larger studies and randomized control trials on the use of pentoxifylline in dermatology and more investigation is needed to evaluate its use for many dermatologic conditions. Pentoxifylline's unique mechanism of action as well as its good tolerability, cost-effectiveness, and minimal drug interactions make it a convenient primary or adjunctive option in many dermatological conditions.
KW - dermatology
KW - pentoxifylline
UR - http://www.scopus.com/inward/record.url?scp=85141356490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141356490&partnerID=8YFLogxK
U2 - 10.1111/jocd.15445
DO - 10.1111/jocd.15445
M3 - Review article
C2 - 36208009
AN - SCOPUS:85141356490
SN - 1473-2130
VL - 22
SP - 410
EP - 417
JO - Journal of Cosmetic Dermatology
JF - Journal of Cosmetic Dermatology
IS - 2
ER -